1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
The oral multiple sclerosis (MS) medications market is undergoing a significant transformation as new therapies reshape treatment paradigms for both patients and healthcare providers. Ongoing innovation, streamlined patient management, and emerging regulatory and supply chain considerations mark a dynamic landscape for stakeholders.
Market Snapshot: Oral Multiple Sclerosis Medications
The market for oral MS medications is benefiting from a strategic shift toward patient-centric, convenient treatment options. As oral therapies move from being niche alternatives to becoming standard practice, stakeholders are navigating evolving clinical protocols and regulatory frameworks. A broad range of advanced molecules is now available, supporting better adherence and streamlined monitoring processes. This momentum is further supported by targeted drug development, improved safety profiles, and expanding global access through diverse distribution channels.
Scope & Segmentation of the Oral Multiple Sclerosis Medications Market
- Molecule: Dimethyl Fumarate, Diroximel Fumarate, Fingolimod, Monomethyl Fumarate, Ozanimod, Ponesimod, Siponimod, Teriflunomide
- Drug Class: Dihydroorotate Dehydrogenase Inhibitors, Fumarates (Dimethyl Fumarate, Diroximel Fumarate, Monomethyl Fumarate), Sphingosine 1 Phosphate Receptor Modulators (Fingolimod, Ozanimod, Ponesimod, Siponimod)
- Indication: Clinically Isolated Syndrome, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis (Active)
- Line Of Therapy: First Line, Later Line, Second Line
- Dosage Form: Capsule, Tablet
- Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Specialty Pharmacy
- Regions Covered: Americas (including United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including key countries in Western Europe, Eastern Europe, Middle East, Africa), and Asia-Pacific (including China, India, Japan, Australia, and Southeast Asian nations)
- Key Companies Profiled: Novartis AG, Biogen Inc., Sanofi S.A., Merck KGaA, Johnson & Johnson, Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd, Viatris Inc.
Key Takeaways: Transformation in Oral MS Therapy
- Recent innovations in oral molecule design are redefining clinical protocols by providing solutions that improve patient adherence and reduce adverse effects.
- Healthcare providers are adapting treatment guidelines to integrate new oral agents, broadening therapy options for diverse patient populations.
- Pharmaceutical companies are strengthening supply chain resilience by exploring locally sourced manufacturing and strategic partnerships to limit the impact of regulatory shifts.
- Advanced service models, including digital patient engagement and data analytics, are enabling better monitoring, persistence, and real-world evidence generation.
- Manufacturers are actively engaging in outcome-based contracting and policy discussions to align access and pricing strategies with payer requirements.
- Global and regional market heterogeneity requires tailored strategies for market entry and resource allocation to optimize expansion efforts.
Tariff Impact on the Oral Multiple Sclerosis Medications Market
Recent United States tariff changes have triggered cost adjustments and operational shifts throughout the oral MS therapy supply chain. Manufacturers are revising sourcing strategies and, in many cases, increasing domestic production to mitigate import challenges. These changes are influencing downstream inventory management for specialty and retail pharmacies, creating new considerations for procurement coordination and strategic stock planning. Ongoing advocacy by pharmaceutical companies aims to minimize adverse cost effects on patient access through policy dialogue and contracting innovation.
Methodology & Data Sources
This report integrates systematic secondary research—covering peer-reviewed publications, regulatory materials, and corporate disclosures—with validation via key opinion leader interviews. Findings reflect both empirical evidence and direct industry feedback, offering a balanced perspective that supports robust, actionable insights into the oral multiple sclerosis medications market.
Why This Report Matters
- Enables strategic planning by delivering actionable segmentation and regional insights tailored for executive decision-making.
- Equips stakeholders to proactively address regulatory, supply chain, and market access challenges within the evolving oral MS therapy landscape.
- Supports investment and partnership decisions through independently validated intelligence.
Conclusion
Oral therapeutics are redefining standards in MS care, presenting new avenues for improved patient outcomes and stakeholder alignment. Strategic innovation, regulatory adaptation, and engaged collaboration will drive continued market advancement.
This product will be delivered within 1-3 business days.
Table of Contents
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rising adoption of ozanimod driven by improved lymphocyte modulation and safety profile
5.2. Impact of oral cladribine cost containment strategies on payer formulary positionings
5.3. Integration of digital monitoring tools to support real-time adherence in oral MS therapies
5.4. Emergence of B cell-targeted small molecule therapies reshaping treatment sequencing in MS
5.5. Competitive pressures reshaping pricing of S1P receptor modulators in major global MS markets
5.6. Strategic partnerships accelerating next-generation oral remyelination agents development pipelines
5.7. Impact of impending fingolimod generic entries on branded S1P modulator market share and pricing dynamics
5.2. Impact of oral cladribine cost containment strategies on payer formulary positionings
5.3. Integration of digital monitoring tools to support real-time adherence in oral MS therapies
5.4. Emergence of B cell-targeted small molecule therapies reshaping treatment sequencing in MS
5.5. Competitive pressures reshaping pricing of S1P receptor modulators in major global MS markets
5.6. Strategic partnerships accelerating next-generation oral remyelination agents development pipelines
5.7. Impact of impending fingolimod generic entries on branded S1P modulator market share and pricing dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
6.2. PESTLE Analysis
8. Oral Medications for Multiple Sclerosis Market, by Molecule
8.1. Introduction
8.2. Dimethyl Fumarate
8.3. Diroximel Fumarate
8.4. Fingolimod
8.5. Monomethyl Fumarate
8.6. Ozanimod
8.7. Ponesimod
8.8. Siponimod
8.9. Teriflunomide
8.2. Dimethyl Fumarate
8.3. Diroximel Fumarate
8.4. Fingolimod
8.5. Monomethyl Fumarate
8.6. Ozanimod
8.7. Ponesimod
8.8. Siponimod
8.9. Teriflunomide
9. Oral Medications for Multiple Sclerosis Market, by Drug Class
9.1. Introduction
9.2. Dihydroorotate Dehydrogenase Inhibitors
9.2.1. Teriflunomide
9.3. Fumarates
9.3.1. Dimethyl Fumarate
9.3.2. Diroximel Fumarate
9.3.3. Monomethyl Fumarate
9.4. Sphingosine 1 Phosphate Receptor Modulators
9.4.1. Fingolimod
9.4.2. Ozanimod
9.4.3. Ponesimod
9.4.4. Siponimod
9.2. Dihydroorotate Dehydrogenase Inhibitors
9.2.1. Teriflunomide
9.3. Fumarates
9.3.1. Dimethyl Fumarate
9.3.2. Diroximel Fumarate
9.3.3. Monomethyl Fumarate
9.4. Sphingosine 1 Phosphate Receptor Modulators
9.4.1. Fingolimod
9.4.2. Ozanimod
9.4.3. Ponesimod
9.4.4. Siponimod
10. Oral Medications for Multiple Sclerosis Market, by Indication
10.1. Introduction
10.2. Clinically Isolated Syndrome
10.3. Relapsing Remitting Multiple Sclerosis
10.4. Secondary Progressive Multiple Sclerosis Active
10.2. Clinically Isolated Syndrome
10.3. Relapsing Remitting Multiple Sclerosis
10.4. Secondary Progressive Multiple Sclerosis Active
11. Oral Medications for Multiple Sclerosis Market, by Line of Therapy
11.1. Introduction
11.2. First Line
11.3. Later Line
11.4. Second Line
11.2. First Line
11.3. Later Line
11.4. Second Line
12. Oral Medications for Multiple Sclerosis Market, by Dosage Form
12.1. Introduction
12.2. Capsule
12.3. Tablet
12.2. Capsule
12.3. Tablet
13. Oral Medications for Multiple Sclerosis Market, by Distribution Channel
13.1. Introduction
13.2. Hospital Pharmacy
13.3. Retail Pharmacy
13.4. Specialty Pharmacy
13.2. Hospital Pharmacy
13.3. Retail Pharmacy
13.4. Specialty Pharmacy
14. Americas Oral Medications for Multiple Sclerosis Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Oral Medications for Multiple Sclerosis Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Oral Medications for Multiple Sclerosis Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Novartis AG
17.3.2. Biogen Inc.
17.3.3. Sanofi S.A.
17.3.4. Merck KGaA
17.3.5. Johnson & Johnson
17.3.6. Bristol-Myers Squibb Company
17.3.7. Teva Pharmaceutical Industries Ltd
17.3.8. Viatris Inc.
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Novartis AG
17.3.2. Biogen Inc.
17.3.3. Sanofi S.A.
17.3.4. Merck KGaA
17.3.5. Johnson & Johnson
17.3.6. Bristol-Myers Squibb Company
17.3.7. Teva Pharmaceutical Industries Ltd
17.3.8. Viatris Inc.
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET: RESEARCHAI
FIGURE 28. ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET: RESEARCHSTATISTICS
FIGURE 29. ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET: RESEARCHCONTACTS
FIGURE 30. ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET: RESEARCHARTICLES
FIGURE 2. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET: RESEARCHAI
FIGURE 28. ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET: RESEARCHSTATISTICS
FIGURE 29. ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET: RESEARCHCONTACTS
FIGURE 30. ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIMETHYL FUMARATE, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIMETHYL FUMARATE, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIROXIMEL FUMARATE, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIROXIMEL FUMARATE, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FINGOLIMOD, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FINGOLIMOD, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MONOMETHYL FUMARATE, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MONOMETHYL FUMARATE, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY OZANIMOD, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY OZANIMOD, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY PONESIMOD, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY PONESIMOD, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SIPONIMOD, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SIPONIMOD, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY TERIFLUNOMIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY TERIFLUNOMIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIHYDROOROTATE DEHYDROGENASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIHYDROOROTATE DEHYDROGENASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY TERIFLUNOMIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY TERIFLUNOMIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIHYDROOROTATE DEHYDROGENASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIHYDROOROTATE DEHYDROGENASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIMETHYL FUMARATE, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIMETHYL FUMARATE, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIROXIMEL FUMARATE, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIROXIMEL FUMARATE, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MONOMETHYL FUMARATE, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MONOMETHYL FUMARATE, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FINGOLIMOD, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FINGOLIMOD, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY OZANIMOD, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY OZANIMOD, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY PONESIMOD, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY PONESIMOD, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SIPONIMOD, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SIPONIMOD, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY CLINICALLY ISOLATED SYNDROME, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY CLINICALLY ISOLATED SYNDROME, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY RELAPSING REMITTING MULTIPLE SCLEROSIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY RELAPSING REMITTING MULTIPLE SCLEROSIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS ACTIVE, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS ACTIVE, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LATER LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LATER LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY CAPSULE, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY TABLET, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIHYDROOROTATE DEHYDROGENASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIHYDROOROTATE DEHYDROGENASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIHYDROOROTATE DEHYDROGENASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIHYDROOROTATE DEHYDROGENASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 121. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 122. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 123. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 124. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 125. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 126. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 127. CANADA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 128. CANADA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 129. CANADA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 130. CANADA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 131. CANADA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIHYDROOROTATE DEHYDROGENASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 132. CANADA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIHYDROOROTATE DEHYDROGENASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 133. CANADA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2024 (USD MILLION)
TABLE 134. CANADA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2025-2030 (USD MILLION)
TABLE 135. CANADA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
TABLE 136. CANADA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2025-2030 (USD MILLION)
TABLE 137. CANADA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 138. CANADA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 139. CANADA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 140. CANADA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 141. CANADA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 142. CANADA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 143. CANADA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 144. CANADA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 145. MEXICO ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 146. MEXICO ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 147. MEXICO ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 148. MEXICO ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 149. MEXICO ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIHYDROOROTATE DEHYDROGENASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 150. MEXICO ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIHYDROOROTATE DEHYDROGENASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 151. MEXICO ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2024 (USD MILLION)
TABLE 152. MEXICO ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2025-2030 (USD MILLION)
TABLE 153. MEXICO ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
TABLE 154. MEXICO ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2025-2030 (USD MILLION)
TABLE 155. MEXICO ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 156. MEXICO ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 157. MEXICO ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 158. MEXICO ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 159. MEXICO ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 160. MEXICO ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 161. MEXICO ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 162. MEXICO ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 163. BRAZIL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 164. BRAZIL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 165. BRAZIL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 166. BRAZIL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 167. BRAZIL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIHYDROOROTATE DEHYDROGENASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 168. BRAZIL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIHYDROOROTATE DEHYDROGENASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 169. BRAZIL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2024 (USD MILLION)
TABLE 170. BRAZIL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2025-2030 (USD MILLION)
TABLE 171. BRAZIL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
TABLE 172. BRAZIL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2025-2030 (USD MILLION)
TABLE 173. BRAZIL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 174. BRAZIL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 175. BRAZIL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 176. BRAZIL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 177. BRAZIL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 178. BRAZIL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 179. BRAZIL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 180. BRAZIL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 181. ARGENTINA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 182. ARGENTINA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 183. ARGENTINA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 184. ARGENTINA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 185. ARGENTINA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIHYDROOROTATE DEHYDROGENASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 186. ARGENTINA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIHYDROOROTATE DEHYDROGENASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 187. ARGENTINA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2024 (USD MILLION)
TABLE 188. ARGENTINA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2025-2030 (USD MILLION)
TABLE 189. ARGENTINA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
TABLE 190. ARGENTINA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2025-2030 (USD MILLION)
TABLE 191. ARGENTINA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 192. ARGENTINA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 193. ARGENTINA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 194. ARGENTINA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 195. ARGENTINA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 196. ARGENTINA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 197. ARGENTINA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 198. ARGENTINA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIHYDROOROTATE DEHYDROGENASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIHYDROOROTATE DEHYDROGENASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 205. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2024 (USD MILLION)
TABLE 206. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2025-2030 (USD MILLION)
TABLE 207. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
TABLE 208. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2025-2030 (USD MILLION)
TABLE 209. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 210. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 211. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 212. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 213. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 214. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 215. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 216. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 217. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 218. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 219. UNITED KINGDOM ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 220. UNITED KINGDOM ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 221. UNITED KINGDOM ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 222. UNITED KINGDOM ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 223. UNITED KINGDOM ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIHYDROOROTATE DEHYDROGENASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 224. UNITED KINGDOM ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIHYDROOROTATE DEHYDROGENASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 225. UNITED KINGDOM ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2024 (USD MILLION)
TABLE 226. UNITED KINGDOM ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2025-2030 (USD MILLION)
TABLE 227. UNITED KINGDOM ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
TABLE 228. UNITED KINGDOM ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2025-2030 (USD MILLION)
TABLE 229. UNITED KINGDOM ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 230. UNITED KINGDOM ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 231. UNITED KINGDOM ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 232. UNITED KINGDOM ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 234. UNITED KINGDOM ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 235. UNITED KINGDOM ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 236. UNITED KINGDOM ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 237. GERMANY ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 238. GERMANY ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 239. GERMANY ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 240. GERMANY ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 241. GERMANY ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIHYDROOROTATE DEHYDROGENASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 242. GERMANY ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIHYDROOROTATE DEHYDROGENASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 243. GERMANY ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2024 (USD MILLION)
TABLE 244. GERMANY ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2025-2030 (USD MILLION)
TABLE 245. GERMANY ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
TABLE 246. GERMANY ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2025-2030 (USD MILLION)
TABLE 247. GERMANY ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 248. GERMANY ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 249. GERMANY ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 250. GERMANY ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 251. GERMANY ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 252. GERMANY ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 253. GERMANY ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 254. GERMANY ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 255. FRANCE ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 256. FRANCE ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 257. FRANCE ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 258. FRANCE ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 259. FRANCE ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIHYDROOROTATE DEHYDROGENASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 260. FRANCE ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIHYDROOROTATE DEHYDROGENASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 261. FRANCE ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2024 (USD MILLION)
TABLE 262. FRANCE ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2025-2030 (USD MILLION)
TABLE 263. FRANCE ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
TABLE 264. FRANCE ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2025-2030 (USD MILLION)
TABLE 265. FRANCE ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 266. FRANCE ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 267. FRANCE ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 268. FRANCE ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 26
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIMETHYL FUMARATE, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIMETHYL FUMARATE, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIROXIMEL FUMARATE, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIROXIMEL FUMARATE, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FINGOLIMOD, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FINGOLIMOD, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MONOMETHYL FUMARATE, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MONOMETHYL FUMARATE, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY OZANIMOD, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY OZANIMOD, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY PONESIMOD, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY PONESIMOD, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SIPONIMOD, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SIPONIMOD, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY TERIFLUNOMIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY TERIFLUNOMIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIHYDROOROTATE DEHYDROGENASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIHYDROOROTATE DEHYDROGENASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY TERIFLUNOMIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY TERIFLUNOMIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIHYDROOROTATE DEHYDROGENASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIHYDROOROTATE DEHYDROGENASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIMETHYL FUMARATE, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIMETHYL FUMARATE, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIROXIMEL FUMARATE, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIROXIMEL FUMARATE, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MONOMETHYL FUMARATE, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MONOMETHYL FUMARATE, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FINGOLIMOD, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FINGOLIMOD, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY OZANIMOD, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY OZANIMOD, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY PONESIMOD, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY PONESIMOD, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SIPONIMOD, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SIPONIMOD, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY CLINICALLY ISOLATED SYNDROME, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY CLINICALLY ISOLATED SYNDROME, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY RELAPSING REMITTING MULTIPLE SCLEROSIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY RELAPSING REMITTING MULTIPLE SCLEROSIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS ACTIVE, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS ACTIVE, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LATER LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LATER LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY CAPSULE, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY TABLET, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIHYDROOROTATE DEHYDROGENASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIHYDROOROTATE DEHYDROGENASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIHYDROOROTATE DEHYDROGENASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIHYDROOROTATE DEHYDROGENASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 121. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 122. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 123. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 124. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 125. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 126. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 127. CANADA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 128. CANADA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 129. CANADA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 130. CANADA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 131. CANADA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIHYDROOROTATE DEHYDROGENASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 132. CANADA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIHYDROOROTATE DEHYDROGENASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 133. CANADA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2024 (USD MILLION)
TABLE 134. CANADA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2025-2030 (USD MILLION)
TABLE 135. CANADA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
TABLE 136. CANADA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2025-2030 (USD MILLION)
TABLE 137. CANADA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 138. CANADA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 139. CANADA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 140. CANADA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 141. CANADA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 142. CANADA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 143. CANADA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 144. CANADA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 145. MEXICO ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 146. MEXICO ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 147. MEXICO ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 148. MEXICO ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 149. MEXICO ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIHYDROOROTATE DEHYDROGENASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 150. MEXICO ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIHYDROOROTATE DEHYDROGENASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 151. MEXICO ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2024 (USD MILLION)
TABLE 152. MEXICO ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2025-2030 (USD MILLION)
TABLE 153. MEXICO ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
TABLE 154. MEXICO ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2025-2030 (USD MILLION)
TABLE 155. MEXICO ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 156. MEXICO ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 157. MEXICO ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 158. MEXICO ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 159. MEXICO ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 160. MEXICO ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 161. MEXICO ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 162. MEXICO ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 163. BRAZIL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 164. BRAZIL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 165. BRAZIL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 166. BRAZIL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 167. BRAZIL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIHYDROOROTATE DEHYDROGENASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 168. BRAZIL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIHYDROOROTATE DEHYDROGENASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 169. BRAZIL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2024 (USD MILLION)
TABLE 170. BRAZIL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2025-2030 (USD MILLION)
TABLE 171. BRAZIL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
TABLE 172. BRAZIL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2025-2030 (USD MILLION)
TABLE 173. BRAZIL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 174. BRAZIL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 175. BRAZIL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 176. BRAZIL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 177. BRAZIL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 178. BRAZIL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 179. BRAZIL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 180. BRAZIL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 181. ARGENTINA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 182. ARGENTINA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 183. ARGENTINA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 184. ARGENTINA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 185. ARGENTINA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIHYDROOROTATE DEHYDROGENASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 186. ARGENTINA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIHYDROOROTATE DEHYDROGENASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 187. ARGENTINA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2024 (USD MILLION)
TABLE 188. ARGENTINA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2025-2030 (USD MILLION)
TABLE 189. ARGENTINA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
TABLE 190. ARGENTINA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2025-2030 (USD MILLION)
TABLE 191. ARGENTINA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 192. ARGENTINA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 193. ARGENTINA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 194. ARGENTINA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 195. ARGENTINA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 196. ARGENTINA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 197. ARGENTINA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 198. ARGENTINA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIHYDROOROTATE DEHYDROGENASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIHYDROOROTATE DEHYDROGENASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 205. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2024 (USD MILLION)
TABLE 206. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2025-2030 (USD MILLION)
TABLE 207. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
TABLE 208. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2025-2030 (USD MILLION)
TABLE 209. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 210. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 211. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 212. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 213. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 214. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 215. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 216. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 217. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 218. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 219. UNITED KINGDOM ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 220. UNITED KINGDOM ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 221. UNITED KINGDOM ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 222. UNITED KINGDOM ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 223. UNITED KINGDOM ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIHYDROOROTATE DEHYDROGENASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 224. UNITED KINGDOM ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIHYDROOROTATE DEHYDROGENASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 225. UNITED KINGDOM ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2024 (USD MILLION)
TABLE 226. UNITED KINGDOM ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2025-2030 (USD MILLION)
TABLE 227. UNITED KINGDOM ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
TABLE 228. UNITED KINGDOM ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2025-2030 (USD MILLION)
TABLE 229. UNITED KINGDOM ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 230. UNITED KINGDOM ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 231. UNITED KINGDOM ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 232. UNITED KINGDOM ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 234. UNITED KINGDOM ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 235. UNITED KINGDOM ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 236. UNITED KINGDOM ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 237. GERMANY ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 238. GERMANY ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 239. GERMANY ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 240. GERMANY ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 241. GERMANY ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIHYDROOROTATE DEHYDROGENASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 242. GERMANY ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIHYDROOROTATE DEHYDROGENASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 243. GERMANY ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2024 (USD MILLION)
TABLE 244. GERMANY ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2025-2030 (USD MILLION)
TABLE 245. GERMANY ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
TABLE 246. GERMANY ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2025-2030 (USD MILLION)
TABLE 247. GERMANY ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 248. GERMANY ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 249. GERMANY ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 250. GERMANY ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 251. GERMANY ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 252. GERMANY ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 253. GERMANY ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 254. GERMANY ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 255. FRANCE ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 256. FRANCE ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 257. FRANCE ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 258. FRANCE ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 259. FRANCE ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIHYDROOROTATE DEHYDROGENASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 260. FRANCE ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIHYDROOROTATE DEHYDROGENASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 261. FRANCE ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2024 (USD MILLION)
TABLE 262. FRANCE ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2025-2030 (USD MILLION)
TABLE 263. FRANCE ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
TABLE 264. FRANCE ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2025-2030 (USD MILLION)
TABLE 265. FRANCE ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 266. FRANCE ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 267. FRANCE ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 268. FRANCE ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 26
Samples
LOADING...
Companies Mentioned
The companies profiled in this Oral Medications for Multiple Sclerosis market report include:- Novartis AG
- Biogen Inc.
- Sanofi S.A.
- Merck KGaA
- Johnson & Johnson
- Bristol-Myers Squibb Company
- Teva Pharmaceutical Industries Ltd
- Viatris Inc.
